Histogen Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-12-16: Form 8-K; Period of report 2021-12-15; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; Details 1.01.
- 2021-11-10: Form 8-K; Period of report 2021-11-08; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2021-11-10: Form 8-K; Period of report 2021-11-10; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2021-11-08: Form 8-K; Period of report 2021-11-05; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-12-16 | 8-K | 2021-12-15 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 The information contained above in Item 1.01 related to the Shares, Warrants and Placement Agent Warrants and the shares of Common Stock issuable thereunder is hereby incorporated by reference into this Item 3.02. 8.01 On December 16, 2021, the Company issued a press release regarding the transactions described above under Item 1.01 of this Current Report on Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | d133087d8k.htm |
| 2021-11-10 | 8-K | 2021-11-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 8, 2021, the Board of Directors (the “Board”) of Histogen Inc. (the “Company”) approved retention related compensation adjustments for certain executive officers of the Company, including Susan A. Knudson, the Company’s Executive Vice President and Chief Financial Officer and the principal accounting officer and a named executive officer of the Company. | hsto-8k_20211108.htm |
| 2021-11-10 | 8-K | 2021-11-10 | 2.02 Results of Operations and Financial Condition | 2.02 On November 10, 2021, Histogen Inc. (the “Company”) issued a press release announcing its results of operations for the three and nine months ended September 30, 2021. | hsto-8k_20211110.htm |
| 2021-11-08 | 8-K | 2021-11-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On November 8, 2021, Richard Pascoe stepped down from his position as President and Chief Executive Officer of Histogen Inc. (the “Company”) and as a member of the Company’s Board of Directors (the “Board”). 8.01 On November 8, 2021, the Company issued a press release regarding Mr. Pascoe’s resignation and the appointment of Dr. Mento as described above under Item 5.02 of this Current Report on Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | d156115d8k.htm |
| 2021-08-20 | 8-K | 2021-08-18 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | hsto-8k_20210818.htm | |
| 2021-08-11 | 8-K | 2021-08-11 | 2.02 Results of Operations and Financial Condition | 2.02 On August 11, 2021, Histogen Inc. (the “Company”) issued a press release announcing its results of operations for the three and six months ended June 30, 2021. | hsto-8k_20210811.htm |
| 2021-06-25 | 8-K | 2021-06-25 | 1.01 Entry into a Material Definitive Agreement | hsto-8k_20210625.htm | |
| 2021-06-09 | 8-K | 2021-06-09 | 8.01 Other Events | hsto-8k_20210609.htm | |
| 2021-06-08 | 8-K | 2021-06-07 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 The information contained above in Item 1.01 related to the Warrants and the Placement Agent Warrants and the shares of Common Stock issuable thereunder is hereby incorporated by reference into this Item 3.02. 8.01 On June 7, 2021, the Company issued a press release regarding the transactions described above under Item 1.01 of this Current Report on Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | d358413d8k.htm |
| 2021-06-03 | 8-K | 2021-06-03 | 8.01 Other Events | hsto-8k_20210603.htm | |
| 2021-05-27 | 8-K | 2021-05-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On May 26, 2021, Histogen Inc. (the “Company”) and Gail K. Naughton, Ph.D. entered into a Confidential Severance Agreement and General Release pursuant to which Dr. Naughton’s employment as the Company’s Chief Scientific Officer will end as of May 31, 2021 (the “Severance Agreement”). | hsto-8k_20210526.htm |
| 2021-05-13 | 8-K | 2021-05-13 | 2.02 Results of Operations and Financial Condition | hsto-8k_20210513.htm | |
| 2021-03-25 | 8-K | 2021-03-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On March 24, 2021, Stephen Chang, Ph.D. resigned as a Director of Histogen Inc. (the “Company”), effective immediately. | hsto-8k_20210324.htm |
| 2021-03-11 | 8-K | 2021-03-11 | 2.02 Results of Operations and Financial Condition | hsto-8k_20210311.htm | |
| 2021-03-10 | 8-K | 2021-03-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On March 10, 2021, Yizhuo (“Hayden”) Zhang resigned as a Director of Histogen Inc. (the “Company”), effective immediately. | hsto-8k_20210310.htm |
| 2021-01-19 | 8-K | 2021-01-15 | 8.01 Other Events | 8.01 On January 19, 2021, the Company issued a news release announcing an update for its HST-003 knee cartilage regeneration program. | d113639d8k.htm |
| 2021-01-05 | 8-K | 2020-12-30 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On January 5, 2021, Histogen Inc. (the “Company”) completed a public offering (the “Offering”) of (i) 11,600,000 shares of its common stock, par value $0.0001 per share (the “Common Stock”), (ii) pre-funded warrants to purchase up to 2,400,000 shares of Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase up to 14,000,000 shares of Common Stock (the “Common Warrants”). | d103306d8k.htm |